Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics [Yahoo! Finance]
ASTELLAS PHARMA UNSP/ADR (ALPMY)
NASDAQ:AMEX Investor Relations:
astellas.com/jp/en/investors
Company Research
Source: Yahoo! Finance
TOKYO and BOSTON Feb. 15, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") and Kelonia Therapeutics (CEO, Founder: Kevin Friedman , Ph.D., "Kelonia") today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos") and Kelonia have entered into a research collaboration and license agreement to develop novel Immuno-Oncology therapeutics. Kelonia is a biotech company pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS ® ). iGPS ® uses next generation lentiviral particles to efficiently deliver genetic cargo precisely to the desired target cells inside the patient's body. Xyphos holds a novel and proprietary ACCEL™ technology* platform that uses its convertible CAR ® (convertible Chimeric Antigen Receptor)* on immune cells. Under the terms of the agreement, the companies plan to combine Kelonia's iGPS ® with Xyphos' ACCEL™ technology to develop innovative in vivo
Show less
Read more
Impact Snapshot
Event Time:
ALPMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALPMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALPMY alerts
High impacting ASTELLAS PHARMA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
ALPMY
News
- Bayer Menopause Drug Shows Positive Result in Late-Stage Trials [BNN Bloomberg (Canada)]BNN Bloomberg
- Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor [Yahoo! Finance]Yahoo! Finance
- Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech CorridorPR Newswire
- Announcing More Customer Expansions [Yahoo! Finance]Yahoo! Finance